Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 2:27 AM ET


Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

34 Employees





Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $466.0K
Chief Financial Officer
Age: 47
Total Annual Compensation: $318.9K
Senior Vice President of Drug Development
Age: 54
Total Annual Compensation: $277.5K
Chief Scientific Officer and Executive Vice President
Age: 46
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2014.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015

Ardelyx, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015 . Venue: Mandarin Oriental New York, 80 Columbus Circle, New York, NY 10023, United States.

Ardelyx, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 02:30 PM

Ardelyx, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 02:30 PM. Venue: Sofitel Hotel, New York, New York, United States.

Ardelyx, Inc. Announces Termination of Option and License Agreement with Sanofi

On September 1, 2015, Ardelyx, Inc. (the Company) announced that Sanofi S.A. (Sanofi) notified the company of its termination of the option and license agreement for the company's portfolio of NaP2b inhibitors, effective on September 30, 2015. There was no payment associated with termination and the return of rights to Ardelyx. In February 2014, the company and Sanofi entered into an option and license agreement under which the company granted Sanofi an exclusive worldwide license to conduct research utilizing the company's small molecule NaP2b inhibitors, also called RDX002, for the treatment of hyperphosphatemia in ESRD patients. If a development candidate were identified within a defined period, Sanofi could exercise its option to obtain an exclusive license to develop, manufacture and commercialize the company's NaP2b inhibitors. The company received an upfront payment of $1.25 million upon execution of the agreement. The NaP2b inhibitors are all in early research phase.

Similar Private Companies By Industry

Company Name Region
Protometrix, Inc. United States
Tempero Pharmaceuticals, Inc. United States
CoTherix, Inc. United States
Pono Corp. United States
Rosetta Inpharmatics LLC United States

Recent Private Companies Transactions

Private Placement
June 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardelyx, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at